| |
Original Artikel |
Datum |
Titel |
Autoren Max. 6 Autoren |
| 1 |
[GO] |
2024―Aug―15 |
Are protein-ligand docking programs good enough to predict experimental poses of noncovalent ligands bound to the SARS-CoV-2 main protease? |
Ariadna Llop-Peiró, Guillem Macip, Santiago Garcia-Vallvé, Gerard Pujadas |
| 2 |
[GO] |
2024―Aug―02 |
An overview of the development of pharmacotherapeutics targeting SARS-CoV-2 |
Tom Lucaj, Ian Hay, Amirreza Samarbakhsh, Mel Bedi, Arun K. Iyer, Navnath S. Gavande |
| 3 |
[GO] |
2024―Mai―17 |
Targeting furin, a cellular proprotein convertase, for COVID-19 prevention and therapeutics |
Xia Jiang, Dabing Li, Mazaher Maghsoudloo, Xinghai Zhang, Wenzhe Ma, Junjiang Fu |
| 4 |
[GO] |
2023―Nov―28 |
Targeted degrader technologies as prospective SARS-CoV-2 therapies |
Rabia Khurshid, Joseph M. Schulz, Jiaming Hu, Timothy S. Snowden, Robert C. Reynolds, Stephan C. Schürer |
| 5 |
[GO] |
2023―Nov―16 |
Targeting SARS-CoV-2 nonstructural protein 3: function, structure, inhibition, and perspective in drug discovery |
Xin Li, Yongcheng Song |
| 6 |
[GO] |
2023―Sep―01 |
Deadly interactions: synergistic manipulations of concurrent pathogen infections potentially enabling future pandemics |
Kevin Roe |
| 7 |
[GO] |
2023―Jul―28 |
Analyzing 3D structures of the SARS-CoV-2 main protease reveals structural features of ligand binding for COVID-19 drug discovery |
Liang Xu, Ru Chen, Jie Liu, Tucker A Patterson, Huixiao Hong |
| 8 |
[GO] |
2023―Jul―22 |
Learning from COVID-19: How drug hunters can prepare for the next pandemic |
Ana C. Puhl, Thomas Lane, Sean Ekins |
| 9 |
[GO] |
2023―Jun―12 |
Harnessing aptamers against COVID-19: a therapeutic strategy |
Ali Mahmoudi, Seyedeh Hoda Alavizadeh, Seyedeh Atefeh Hosseini, Pouria Meidany, Maham Doagooyan, Yasaman Abolhasani, Zakieh Saadat, Fatemeh Amani, Prashant Kesharwani, Fatemeh Gheybi, Amirhossein Sahebkar |
| 10 |
[GO] |
2023―Apr―05 |
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease |
Thales Kronenberger, Stefan A. Laufer, Thanigaimalai Pillaiyar |
| 11 |
[GO] |
2022―Sep―06 |
COVID-19 and fibrosis: mechanisms, clinical relevance, and future perspectives |
Mohd Aslam Saifi, Sapana Bansod, Chandraiah Godugu |
| 12 |
[GO] |
2022―Aug―19 |
The current status of COVID-19 vaccines. a scoping review |
Manuel Rueda-Fernández, Lucía Melguizo-Rodríguez, Víctor J. Costela-Ruiz, Anabel González-Acedo, Javier Ramos-Torrecillas, Rebeca Illescas-Montes |
| 13 |
[GO] |
2022―Jul―28 |
Nanosponges: an overlooked promising strategy to combat SARS-CoV-2 |
Ebrahim Mostafavi, Siavash Iravani, Rajender S. Varma |
| 14 |
[GO] |
2022―Jul―26 |
Impact of COVID-19 on male urogenital health: success of vaccines |
Kutay Kucukyildiz, Didem Yilmaz-Oral, Damla Turkcan, Cetin Volkan Oztekin, Serap Gur |
| 15 |
[GO] |
2022―Jul―04 |
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein |
Saroj Verma, Vaishali M. Patil, Manish K. Gupta |
| 16 |
[GO] |
2022―Apr―06 |
Repurposing drugs as COVID-19 therapies: a toxicity evaluation |
Deborah K. Ngan, Tuan Xu, Menghang Xia, Wei Zheng, Ruili Huang |
| 17 |
[GO] |
2022―Feb―19 |
Efficacy of repurposed antiviral drugs: lessons from COVID-19 |
Miguel Angel Martinez |
| 18 |
[GO] |
2022―Feb―10 |
Drug repurposing against SARS-CoV-2 using computational approaches |
Sumit Kumar, Svitlana Kovalenko, Shakshi Bhardwaj, Aaftaab Sethi, Nikolay Yu. Gorobets, Sergey M. Desenko, Brijesh Rathi |
| 19 |
[GO] |
2021―Dez―23 |
Organoid and microfluidics-based platforms for drug screening in COVID-19 |
Roya Ramezankhani, Roya Solhi, Yoke Chin Chai, Massoud Vosough, Catherine Verfaillie |
| 20 |
[GO] |
2021―Dez―23 |
Applications of density functional theory in COVID-19 drug modeling |
Naike Ye, Zekai Yang, Yuchen Liu |
| 21 |
[GO] |
2021―Dez―11 |
Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs |
Rosemarie Bernabe, Cristina Torres, Grace Wangge, Edlyn Jimenez, Juntra Karbwang |
| 22 |
[GO] |
2021―Nov―08 |
The PI3K/Akt/mTOR pathway: a potential pharmacological target in COVID-19 |
Maria Sofia Basile, Eugenio Cavalli, James McCubrey, Jorge Hernández-Bello, José Francisco Muñoz-Valle, Paolo Fagone, Ferdinando Nicoletti |
| 23 |
[GO] |
2021―Okt―29 |
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling |
Gajjela Bharath Kumar, Ming-Ming Zhou |
| 24 |
[GO] |
2021―Okt―19 |
Integrating heterogeneous data to facilitate COVID-19 drug repurposing |
Lucía Prieto Santamaría, Marina Díaz Uzquiano, Esther Ugarte Carro, Nieves Ortiz-Roldán, Yuliana Pérez Gallardo, Alejandro Rodríguez-González |
| 25 |
[GO] |
2021―Jul―30 |
Advances in the computational landscape for repurposed drugs against COVID-19 |
Illya Aronskyy, Yosef Masoudi-Sobhanzadeh, Antonio Cappuccio, Elena Zaslavsky |
| 26 |
[GO] |
2021―Jul―29 |
Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management |
Vivek P. Chavda, Lalitkumar K. Vora, Anjali K. Pandya, Vandana B. Patravale |
| 27 |
[GO] |
2021―Jul―28 |
Harnessing the power of microphysiological systems for COVID-19 research |
Nicole Kleinstreuer, Anthony Holmes |
| 28 |
[GO] |
2021―Jun―18 |
Recent progress on rapid SARS-CoV-2/COVID-19 detection by CRISPR-Cas13-based platforms |
Guillermo Aquino-Jarquin |
| 29 |
[GO] |
2021―Mai―25 |
High-throughput screening assays for SARS-CoV-2 drug development: current status and future directions |
Tuan Xu, Wei Zheng, Ruili Huang |
| 30 |
[GO] |
2021―Apr―29 |
Revamping the Ever-changing Landscape of Drug Development Processes in the Midst of COVID-19 Pandemic |
Charles Oo, Barbara Ameer |
| 31 |
[GO] |
2021―Apr―21 |
Web resources facilitate drug discovery in treatment of COVID-19 |
Long-Can Mei, Yin Jin, Zheng Wang, Ge-Fei Hao, Guang-Fu Yang |
| 32 |
[GO] |
2021―Apr―21 |
The impact of COVID-19 on the cell and gene therapies industry: disruptions, opportunities, and future prospects |
Tingting Qiu, Yitong Wang, Shuyao Liang, Ru Han, Mondher Toumi |
| 33 |
[GO] |
2021―Apr―16 |
The fight against COVID-19: striking a balance in the renin-angiotensin system |
Alexis Q. Dean, William P. Bozza, Julianne D. Twomey, Shen Luo, Ancy Nalli, Baolin Zhang |
| 34 |
[GO] |
2021―Mrz―26 |
Diabetes, inflammation, and the adiponectin paradox: therapeutic targets in SARS-CoV-2 |
Gilbert Ho, Alysha Ali, Yoshiki Takamatsu, Ryoko Wada, Eliezer Masliah, Makoto Hashimoto |
| 35 |
[GO] |
2021―Feb―21 |
Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition? |
Mary EW Collier, Shaowei Zhang, Nigel S Scrutton, Flaviano Giorgini |
| 36 |
[GO] |
2021―Feb―18 |
Developing new drugs that activate the protective arm of the renin angiotensin system as a potential treatment for respiratory failure in COVID-19 patients |
Mathilde Latil, Serge Camelo, Stanislas Veillet, René Lafont, Pierre J. Dilda |
| 37 |
[GO] |
2021―Jan―23 |
SARS-CoV-2-mediated hyperferritinemia and cardiac arrest: preliminary insights |
Prakash VasanthiDharmalingam, Vengadeshprabhu Karuppagounder, Kenichi Watanabe, Harry Karmouty-Quintana, Suresh S. Palaniyandi, Ashrith Guha, Rajarajan A. Thandavarayan |
| 38 |
[GO] |
2021―Jan―22 |
Drugs acting on the renin-angiotensin system and SARS-CoV-2 |
A. Vitiello, C. Pelliccia, Francesco Ferrara |
| 39 |
[GO] |
2021―Jan―14 |
Modelling the World - can deliberately infecting healthy volunteers really tell us much about what happens outside the clinic during an epidemic or pandemic? |
Adrian Wildfire |
| 40 |
[GO] |
2020―Dez―09 |
Potential SARS-CoV-2 main protease inhibitors |
Riddhidev Banerjee, Lalith Perera, L.M. Viranga Tillekeratne |
| 41 |
[GO] |
2020―Nov―27 |
Expanded Access Programs, compassionate drug Use, and Emergency Use Authorizations during the COVID-19 pandemic |
John G. Rizk, Donald N. Forthal, Kamyar Kalantar-Zadeh, Mandeep R. Mehra, Carl J. Lavie, Youssef Rizk, JoAnn P. Pfeiffer, John C. Lewin |
| 42 |
[GO] |
2020―Okt―27 |
Union is strength: antiviral and anti-inflammatory drugs for COVID-19 |
J. Jesús Naveja, Abraham Madariaga-Mazón, Francisco Flores-Murrieta, Julio Granados-Montiel, Marco Maradiaga-Ceceña, Víctor Duarte Alaniz, Maricruz Maldonado-Rodriguez, Jazmín García-Morales, Juan Pablo Senosiain-Peláez, Karina Martínez-Mayorga |
| 43 |
[GO] |
2020―Okt―06 |
Virus-, host-, immune-based targets for COVID-19 therapy |
Wei Liu, Hai-Liang Zhu, Yongtao Duan |
| 44 |
[GO] |
2020―Sep―16 |
Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms |
Nitesh Sanghai, Geoffrey K. Tranmer |
| 45 |
[GO] |
2020―Sep―01 |
Could PROTACs Protect Us From COVID-19? |
Wilnelly Martinez-Ortiz, Ming-Ming Zhou |
| 46 |
[GO] |
2020―Aug―12 |
Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites |
Sally El Kantar, Bilal Nehmeh, Philippe Saad, Gabie Mitri, Celine Estephan, Mohamad Mroueh, Elias Akoury, Robin I. Taleb |
| 47 |
[GO] |
2020―Aug―07 |
Global clinical trial mobilization for COVID-19: higher, faster, stronger |
Reed F. Beall, Aidan Hollis |
| 48 |
[GO] |
2020―Jul―04 |
Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges |
Raymond Chang, Wei-Zen Sun |
| 49 |
[GO] |
2020―Jun―25 |
Prevention of COVID-19 by drug repurposing: rationale from drugs prescribed for mental disorders |
Bruno O. Villoutreix, Philippe H. Beaune, Ryad Tamouza, Rajogapal Krishnamoorthy, Marion Leboyer |
| 50 |
[GO] |
2020―Jun―24 |
Emerging vaccine delivery systems for COVID-19 |
Nigel Theobald |
| 51 |
[GO] |
2020―Jun―24 |
Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19 |
Rajendran J.C. Bose, Jason R. McCarthy |
| 52 |
[GO] |
2020―Jun―20 |
Current and future therapeutical approaches for COVID-19 |
Yongtao Duan, Yongfang Yao, Senthil Arun Kumar, Hai-Liang Zhu, Junbiao Chang |
| 53 |
[GO] |
2020―Jun―20 |
Discovering small-molecule therapeutics against SARS-CoV-2 |
Vaibhav Tiwari, Jacob C. Beer, Nehru Viji Sankaranarayanan, Michelle Swanson-Mungerson, Umesh R. Desai |
| 54 |
[GO] |
2020―Jun―18 |
COVID-19 and pneumonia: a role for the uPA/uPAR system |
Daniele D’Alonzo, Maria De Fenza, Vincenzo Pavone |
| 55 |
[GO] |
2020―Mai―13 |
Shotgun drug repurposing biotechnology to tackle epidemics and pandemics |
William Mangione, Zackary Falls, Thomas Melendy, Gaurav Chopra, Ram Samudrala |
| 56 |
[GO] |
2020―Mai―06 |
Extracellular vesicles from mesenchymal stem cells as a Covid-19 treatment |
Lorraine O’Driscoll |
| 57 |
[GO] |
2020―Mai―01 |
Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19 |
Ilaria D’Acquarica, Israel Agranat |
| 58 |
[GO] |
2020―Apr―19 |
Déjà vu: Stimulating open drug discovery for SARS-CoV-2 |
Sean Ekins, Melina Mottin, Paulo R.P.S. Ramos, Bruna K.P. Sousa, Bruno Junior Neves, Daniel H. Foil, Kimberley M. Zorn, Rodolpho C. Braga, Megan Coffee, Christopher Southan, Ana C. Puhl, Carolina Horta Andrade |
| 59 |
[GO] |
2020―Apr―15 |
Boosting the arsenal against COVID-19 through computational drug repurposing |
Gennaro Ciliberto, Luca Cardone |
| 60 |
[GO] |
2020―Mrz―18 |
Advance of promising targets and agents against 2019-nCoV in China |
Yongtao Duan, Hai-Liang Zhu, Chongchen Zhou |
| 61 |
[GO] |
2020―Jan―30 |
Recent discovery and development of inhibitors targeting coronaviruses |
Thanigaimalai Pillaiyar, Sangeetha Meenakshisundaram, Manoj Manickam |
